Therapeutic agent

Montelukast

ModerateEvidence level
1Registered trials
2Conditions
0Study references

Evidence Summary

Evidence Level
Moderate
Mechanism
Enrollment: Actual, Sponsor Type: Other, Unknown / General
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Leukotriene receptor antagonist used as add-on in MCAS and sometimes respiratory phenotypes in long COVID. 10mg daily. Supported by observational MCAS data and urticaria RCTs. Low risk; consider for MCAS-overlap with incomplete antihistamine response.

Clinical Trials

1 trial(s) registered

NCT IDTitlePhaseStatus
NCT04695704Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:Phase 3Terminated

Key Studies / References

  • See linked studies